Lifecore Biomedical (NASDAQ:LFCR) Stock Rating Upgraded by Wall Street Zen

Lifecore Biomedical (NASDAQ:LFCR) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

LFCR has been the subject of several other research reports. Barrington Research increased their price objective on shares of Lifecore Biomedical from $5.50 to $6.00 and gave the company an “outperform” rating in a report on Wednesday, April 29th. Weiss Ratings downgraded shares of Lifecore Biomedical from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Lifecore Biomedical presently has a consensus rating of “Hold” and an average price target of $6.00.

Lifecore Biomedical Stock Down 2.8%

LFCR opened at $5.63 on Friday. The firm has a 50-day simple moving average of $4.76 and a two-hundred day simple moving average of $6.49. Lifecore Biomedical has a 52 week low of $3.63 and a 52 week high of $8.98. The company has a market capitalization of $211.18 million, a PE ratio of -5.99 and a beta of 1.06.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.14). Lifecore Biomedical had a negative net margin of 25.43% and a negative return on equity of 1,643.15%. The company had revenue of $23.19 million for the quarter, compared to the consensus estimate of $25.96 million. As a group, sell-side analysts expect that Lifecore Biomedical will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after acquiring an additional 1,886 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after acquiring an additional 2,786 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Lifecore Biomedical by 20.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock valued at $137,000 after acquiring an additional 2,826 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Lifecore Biomedical by 28.4% in the 4th quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock valued at $132,000 after acquiring an additional 3,574 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Lifecore Biomedical in the 3rd quarter valued at about $28,000. Institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.